• Most Popular
  • Most Shared

TEXT-Crucell in licensing deal with Recepta Biopharma

Fri Nov 2, 2007 3:08am EDT

Stocks

   

Nov 2 (Reuters) - The following statement was released by Crucell (CRCL.AS):

DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. today announced that they have signed a non-exclusive PER.C6 technology research licensing agreement with Brazilian-based Recepta Biopharma S.A.

This agreement allows Recepta Biopharma to use the PER.C6® technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research.

Financial details were not disclosed.


More from Reuters

Photo

Investors seen jumping the gun on airport security

BANGALORE (Reuters) - Investors' optimism surrounding the shares of airport security systems makers could be premature as interest in the companies' products after the Christmas Day plane scare is not expected to translate into immediate orders.

» More Top News
A hiring sign hangs in a window at PETCO in Falls Church, Virginia June 5, 2009.REUTERS/Kevin Lamarque

Dust off your resumes

Employers say they'll be adding headcount in the coming year. Here's where the jobs will be.  Full Article 

ECONOMY
Tiger Woods blows on his putter on the 10th hole during final round play of the Tournament Players Championship golf tournament at the TPC at Sawgrass in Ponte Vedra, Florida May 13, 2007.

Tiger's $12 billion scandal?

Shareholders of Tiger Woods' sponsors discover that along with the upside, there are big downside risks, too, a study shows.  Full Article 

Sports